EPILEPSY
PROGRAMS
ABOUT EPILEPTIC DISORDERS
An epileptic disorder is a chronic neurological condition characterized by recurrent epileptic seizures. Epileptic seizures are characterized by a hypersynchrony and hyperexcitability of one, or several, neural networks, leading to the apparition of spontaneous epileptiform events that we record by EEG.
These events can be used as translational decision-making biomarkers for drug discovery.
ADVANTAGES FOR YOUR DRUG DISCOVERY
The Sooner, the Better.
We use Brain oscillatory activity to reveal the efficacy potential of your compound at the preclinical step so you can make early Go/NoGo decisions and in fine give your molecules better chances of further clinical success.
Predictive
Our unique approach is based on a Bedside to Bench strategy. It consists in first identifying disease-related oscillations in the patient brain before translating them into our models. We then assess their stability, pharmacosensitivity before calling them translational biomarkers.
Patient Inspired
Datasets are produced following clinical-like, blinded, crossover protocols.
The outcomes offer high statistical power and robustness, the animals being used as their own control for the entire duration of the study.
Robust
Performed exclusively on in vivo, freely-moving animlals, our EEG based assays provide you with unbiased, reliable and sensitive outcomes, that are independent from behavioral tests.
As non-convulsive, the MTLE mouse is a great example applied to epilepsy drug discovery.
Unbiased
WHY CHOSING THE MTLE MOUSE FOR EPILEPSY PROGRAMS
BENEFITS
The MTLE mouse will be particularly useful to:
-
Evaluate the potentiating or synergistic effects of an AED when combined to other drugs
-
Accurately characterize AED** effects on the brain, revealed by SynapCell's quantitative EEG-based technology
-
Identify the most effective drug associations
-
Benefit from objective and reliable readouts for early selection and validation of lead compounds.
-
Get differential pharmacological profiling after acute treatment with different AEDs
*frequent: about 45/hour in the MTLE mouse
**HPD: Hippocampal Paroxysmal Discharges
***AED: Anti-Epileptic Drug
FEATURES
What it is all about
-
Mesial temporal lobe epilepsy (MTLE) is the most common form of drug-refractory epilepsy
-
The MTLE mouse features most of the morphological and electrophysiological features of human MTLE
-
To date the most predictive model for the first application on the market for Epileptic disorders
-
Validated by an extensive pharmacology of reference drugs
-
Associated with frequent and stable epileptic EEG biomarkers (HPD*) allowing for reliable quantification of discharges
-
Non-convulsive therefore unbiased, non-behavioral related outcomes
-
Part of the Epilepsy Therapy Screening Program (ETSP) since 2013, in close collaboration with the University of Utah
DOWNLOAD YOUR PUBLICATION ON THE MTLE MODEL
ORIGINAL ARTICLE
Differential Effects of Antiepileptic Drugs on Focal Seizures in the
Intrahippocampal Kainate Mouse Model of Mesial Temporal Lobe Epilepsy
Mesial temporal lobe epilepsy (MTLE) is the most common form of drug-refractory epilepsy.
Here, we addressed the pharmacological reactivity of this model to the most commonly used AEDs.
The MTLE mouse model displays a differential sensitivity to AEDs with a greater efficacy of drug that facilitates GABAergic transmission.
This model provides an efficient tool to identify new treatment for drug-resistant forms of focal epilepsies.
